Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for NewAmsterdam Pharma Co NV's EV-to-OCF or its related term are showing as below:
NAMS'
s EV-to-OCF Range Over the Past 10 Years
Min: -39.76 Med: -9.85 Max: -4.96
Current: -18.88
During the past 6 years, the highest EV-to-OCF of NewAmsterdam Pharma Co NV was -4.96. The lowest was -39.76. And the median was -9.85.
NAMS's EV-to-OCF is ranked better than 79.56% of 1409
companies
in the Biotechnology industry
Industry Median: -3.48
vs NAMS: -18.88
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NewAmsterdam Pharma Co NV (NAS:NAMS) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NewAmsterdam Pharma Co NV's PE Ratio (TTM) for today is calculated as:
NewAmsterdam Pharma Co NV's share price for today is $27.96.
NewAmsterdam Pharma Co NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.160.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
NewAmsterdam Pharma Co NV EV-to-OCF Related Terms
NewAmsterdam Pharma Co NV EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewAmsterdam Pharma Co NV EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where NewAmsterdam Pharma Co NV's EV-to-OCF falls into.
NewAmsterdam Pharma Co NV's current Enterprise Value is $2,708.49 Mil.
NewAmsterdam Pharma Co NV's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-143.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NewAmsterdam Pharma Co NV (NAMS) has a EV-to-OCF of -18.88 as of Aug. 08, 2026. According to the industry distribution chart, NewAmsterdam Pharma Co NV ranks #288 out of 1409 companies in the Biotechnology industry, placing it in the top 20.4%.
Is NewAmsterdam Pharma Co NV's EV-to-OCF too high?
NewAmsterdam Pharma Co NV's current EV-to-OCF is -18.88. Based on the distribution chart, NewAmsterdam Pharma Co NV ranks #288 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's EV-to-OCF compare to ARQT and IDYA?
According to the Biotechnology industry distribution chart, NewAmsterdam Pharma Co NV ranks #288 out of 1409 companies for EV-to-OCF. This places NewAmsterdam Pharma Co NV in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. NewAmsterdam Pharma Co NV's current EV-to-OCF is -18.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.42, compared to a current price of $27.96 — trading 168.3% above its estimated fair value. The current EV-to-OCF is -18.88. NewAmsterdam Pharma Co NV's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current EV-to-OCF is -18.88 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued.
The current stock price of $27.96 is trading 168.3% above its estimated GF Value™ of $10.42.
GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.
Key valuation signals for NAMS:
EV-to-OCF: -18.88
GF Value™: $10.42 vs. price of $27.96 (168.3% above fair value)
No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
45GF Score
Get the complete analysis for NAMS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAMS has been successfully added to your 
